Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors
Ryan Ashkar, Darren R. Feldman, Nabil Adra, Mohammad Abu Zaid, Samuel A. Funt, Sandra K. Althouse, Susan M. Perkins, C Snow, Kayla Marie Lazzara, Lina M. Sego, David I. Quinn, Nasser H. Hanna, Lawrence H. Einhorn, Costantine Albany
Topics & Concepts
Brentuximab vedotinMedicineInternal medicineChemotherapyGerm cell tumorsChemotherapy regimenRegimenCD30OncologyGastroenterologyAntibody-drug conjugateSurgeryImmunologyImmunohistochemistryAntibodyMonoclonal antibodyTesticular diseases and treatmentsSarcoma Diagnosis and TreatmentLymphoma Diagnosis and Treatment